Diagnostics Research Group, L.L.C.

Diagnostics Research Group, L. L. C. specializes in clinical trials, focusing on innovative patient-centric methodologies to improve access and efficiency in research.

The company leverages advanced technology to enhance the clinical research landscape. Diagnostics Research Group, L. L. C.

is dedicated to conducting comprehensive clinical trials. Founded in 2000 and headquartered in San Antonio, US, the company was acquired in October 2021 by The IMA Group, a portfolio company of Centre Partners. This acquisition allows for expanded access to medical treatments in San Antonio and South Texas. The founder's specific background is not detailed, and there is no mention of prior companies or funding rounds.

Diagnostics Research Group operates a flexible clinical trial network that provides extensive research services for site-based, hybrid, and fully decentralized clinical trials. The company emphasizes patient-centric approaches, utilizing advanced technology to broaden access for diverse populations. This model supports the establishment of additional patient outreach centers as necessary, ensuring trials are accessible to a wide demographic. Their services cater to sponsors and Contract Research Organizations (CROs), focusing on site proximity, diversity, and high-quality data collection.

The client base includes pharmaceutical companies, biotechnology firms, and research institutions across various markets, including the United States and potential international expansions. The revenue model at Diagnostics Research Group is primarily generated through partnerships and collaborations with sponsors and CROs conducting clinical trials. Their business transactions typically involve service agreements for full-service clinical trial management, including patient recruitment and data management. Revenue is derived from fixed contracts based on the specific scope and complexity of each trial, including fees related to participant enrollment, data collection, and trial management, structured to meet the varying needs of their clients.

The acquisition of Diagnostics Research Group, L. L. C. in October 2021 is poised to enhance The IMA Group's offerings by providing better access to new medical treatments through clinical trial participation in San Antonio and South Texas.

The strategic goal includes broadening clinical research capabilities while utilizing the resources gained from the acquisition to strengthen services. Plans for future growth include expanding into new geographic regions and markets as identified through recent operational assessments, aligning with the overarching goal of enhancing clinical trial accessibility and efficiency.